Neurotech International Ltd (ASX:NTI) Share Price

Company Profile

Business description
Neurotech International Ltd is a clinical-stage biopharmaceutical development company. It is focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. NTI164 is a proprietary broad-spectrum cannabinoid drug candidate with a safety and efficacy profile across several paediatric neurological conditions with high unmet need. The group is working across various clinical programs, which include Autism Spectrum Disorder (ASD), Rett Syndrome, PANDAS/PANS, and Human Pharmacokinetics. It is conducting clinical studies to assess the neuro-protective, anti-inflammatory, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
Contact
55 Collins Street
Suite 102, Level 1
MelbourneVIC3000
AUS
T: +61 394983132
https://www.neurotechinternational.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
18

Recommended

We cut our fair value by 26% but the market has overreacted.

Angus Hewitt, CFA | 18 December 2025

Strong earnings with high projected growth but price is too rich.

William Kerwin, CFA | 18 December 2025

Interim report by financial regulator is a hit to sentiment.

Roy Van Keulen | 17 December 2025

Index	Last price	Change	% Change
All Ordinaries	8,875.70	1.50	0.02%
CAC 40	8,104.21	18.16	0.22%
DAX 40	24,033.95	73.36	0.31%
Dow JONES (US)	47,885.97	228.29	-0.47%
FTSE 100	9,757.19	17.13	-0.18%
HKSE	25,498.13	29.35	0.12%
NASDAQ	22,693.32	418.14	-1.81%
Nikkei 225	49,001.50	510.78	-1.03%
NZX 50 Index	13,256.77	39.14	-0.29%
S&P 500	6,721.43	78.83	-1.16%
S&P/ASX 200	8,588.20	3.00	0.03%
SSE Composite Index	3,876.37	6.09	0.16%